Pfizer Expands Biotechnology Research Collaborations

Pfizer, a leading pharmaceutical company, has recently entered four new biotechnology research collaborations as part of its overall investment strategy to expand its array of therapeutic opportunities and accelerate the discovery of new medicines. This strategic network of alliances, termed Pfizergen, will bolster and expand the company's existing biotechnology ventures, doubling its annual rate of investments in external research collaborations. The company expects further agreements over the remainder of the decade, with much of the expansion directed toward genetic research.

Key Takeaways:

• Pfizer has entered four new biotechnology research collaborations as part of its Pfizergen strategy, which aims to expand its array of therapeutic opportunities and accelerate the discovery of new medicines.
• The company has agreed to collaborate with biotech companies Immusol, Myco Pharmaceuticals, AEA Technology, and Oxford Asymmetry on various research projects.
• The collaborations will focus on genetic research, including the development of ribozyme gene therapy for the treatment of HIV, antifungal research, and the identification of novel genes and their functions using antisense technology.
• Pfizer will provide research and development support, make equity investments in the collaborating companies, and retain manufacturing rights to products developed through the collaborations.
• The company's Investment strategy will further accelerate its position in genomic research, with a focus on discovering new medicines and therapies for various diseases.

Statistics:

• Pfizer has agreed to invest in four new biotechnology research collaborations as part of its Pfizergen strategy.
• The company expects to double its annual rate of investments in external research collaborations.
• The collaborations will focus on genetic research, with a focus on developing new medicines and therapies for various diseases.
• Pfizer has a leading position in traditional drug discovery and is committed to building on its existing gene discovery programs and complementing its existing position.
• The company's research collaborations will generate diverse chemical compounds for screening in high-throughput tests.

Sources:

• Pfizer Company Press Release, /PRNewswire/ -- March 23, 1995
• Kate Robins of Pfizer, 203-441-5448, CONTACT: Pfizer, Inc.